Testing effectiveness (Phase 2)Study completedNCT00093080
What this trial is testing
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Who this might be right for
LeiomyosarcomaLiposarcomaOsteosarcoma+2 more
Merck Sharp & Dohme LLC 216